<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226667</url>
  </required_header>
  <id_info>
    <org_study_id>SLS2009001</org_study_id>
    <nct_id>NCT01226667</nct_id>
  </id_info>
  <brief_title>Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia</brief_title>
  <acronym>Flexdose</acronym>
  <official_title>Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osteoporosis Medical Center, Beverly Hills, CA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Osteoporosis Medical Center, Beverly Hills, CA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 9-week randomized double-blind, multi-center study of 172 patients, who after 1 week
      baseline evaluation are randomized to either fixed dose pregabalin starting at 75 mg BID for
      one week and increased to 150 mg BID for 7 weeks or flexibly dosed pregabalin given BID
      (75-300 mg/d) increased gradually over 4 weeks then maintained at that same dosing for 4
      weeks.It is proposed that use of flexible dosing combined with nightly dosing would have
      similar pain relief to fixed dosing, would improve adherence, would have less side effects
      and would be more likely to improve sleep.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score evaluation by NRS</measure>
    <time_frame>8 weeks</time_frame>
    <description>Least square mean change in Fibromyalgia pain at 8weeks compared to baseline utilizing an 11 point numerical rating scale daily pain diary (0 = no pain to 10 =worst possible pain) performed at daily awakening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>At weeks 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate</measure>
    <time_frame>9 weeks</time_frame>
    <description>Discontinuation rates due to lack of efficacy and discontinuation rates due to adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvements in Wolfe Symptom Severity Score</measure>
    <time_frame>9 weeks</time_frame>
    <description>Wolfe Symptom Severity scales for pain, fatigue, trouble sleeping, trouble with anxiety or depression, trouble thinking or remembering, overall FM severity, problems awaking feeling unrefreshed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Flexible Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flexibly dosed pregabalin given BID (75-300 mg/d) increased gradually over 4 weeks then maintained at that same dosing for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed Dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 mg BID for one week and increased to 150 mg BID for 7 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.
Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly.</description>
    <arm_group_label>Flexible Dose</arm_group_label>
    <arm_group_label>Fixed Dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of fibromyalgia by ACR criteria

          -  ambulatory patients

          -  complete of 5 pain diaries during 1 week evaluation

          -  other inclusion criteria may apply

        Exclusion Criteria:

          -  pregnant or of childbearing potential not using contraceptives

          -  use of pregabalin in the past

          -  concomitant use of opioids or gabapentin

          -  estimated creatinine clearance less than 60

          -  other criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keaton Nasser</last_name>
    <role>Study Director</role>
    <affiliation>Osteoporosis Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart L Silverman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osteoporosis Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Silver MD Inc</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stuart L Silverman MD Inc.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Talbert Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Pointe Clinial Research</name>
      <address>
        <city>Tucson</city>
        <state>California</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affilaites in Medical Specialty</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>July 30, 2012</last_update_submitted>
  <last_update_submitted_qc>July 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibromyalgia</keyword>
  <keyword>lyrica</keyword>
  <keyword>pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

